ABT‐888/NCT01113957.

Trial name or title	A trial of ABT‐888 in combination with temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancer
Methods	Phase II open‐label multicentre RCT
Participants	150 women with recurrent high grade serous OC; must be PR or unable to tolerate platinum‐based therapy
Interventions	ABT‐888 + temozolomide versus PLD
Outcomes	Primary: ORR based on tumour measurements and CA125 levels (assessed every 3 months for 3 years) Secondary: PFS, OS, 12‐month survival rate, 6‐month PFS rate, duration of response, safety and tolerability, QoL
Starting date	Mar 2010
Contact information	Yan Luo (Abbott): yan.luo@abbott.com
Notes	End date: Mar 2013